Micron Technology Stock Falls Despite Beating Earnings Estimates, Analysts Say the Recent 550% Price Surge Was Due for a Correction

Gain Therapeutics is developing oral small-molecule drugs for neurodegenerative diseases, focusing on Parkinson's disease. The company's lead candidate, GT-02287, targets the enzyme glucocerebrosidase, stabilizing the protein to promote activity. Early clinical findings show safety and biomarker signals, with a Phase 2 trial expected to start in Q3. Gain's goal is to address disease biology beyond symptomatic relief, potentially making symptomatic therapy more effective and longer-lasting.